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Comparing interferon-gamma release
assays with tuberculin skin test for
identifying latent tuberculosis infection
that progresses to active tuberculosis:
systematic review and meta-analysis
Peter Auguste1*, Alexander Tsertsvadze2, Joshua Pink1, Rachel Court1, Noel McCarthy2, Paul Sutcliffe1
and Aileen Clarke1
Abstract
Background: Timely and accurate identification of people with latent tuberculosis infection (LTBI) is important for
controlling Mycobacterium tuberculosis (TB). There is no gold standard for diagnosis of LTBI. Screening tests such as
interferon gamma release assays (IGRAs) and tuberculin skin test (TST) provide indirect and imperfect information.
This systematic review compared two types of IGRAs QuantiFERON®-TB Gold In-Tube test (QFT-GIT) and T-SPOT.TB
with TST for identification of LTBI by predicting progression to a diagnosis of active TB in three subgroups: children,
immunocompromised people, and those recently arrived from countries with high TB burden.
Methods: Cohort studies were eligible for inclusion. We searched MEDLINE, EMBASE, the Cochrane Library and
other databases from December 2009 to June 2015. One reviewer screened studies, extracted data, and assessed
risk of bias with cross checking by a second reviewer. Strength of association between test results and incidence
of TB was summarised using cumulative incidence ratios (CIRs with 95% CIs). Summary effect measures: the ratio
of CIRs (R-CIR) with 95% CIs. R-CIRs, were pooled using a random-effects model. Heterogeneity was assessed using
Chi-squared and I2 statistics.
Results: Seventeen studies, mostly of moderate or high risk of bias (five in children, 10 in immunocompromised
people, and two in those recently arrived) were included. In children, while in two studies, there was no significant
difference between QFT-GIT and TST (≥5 mm) (pooled R-CIR = 1.11, 95% CI: 0.71, 1.74), two other studies showed
QFT-GIT to outperform TST (≥10 mm) in identifying LTBI. In immunocompromised people, IGRA (T-SPOT.TB) was
not significant different from TST (≥10 mm) for identifying LTBI, (pooled R-CIR = 1.01, 95% CI: 0.65, 1.58). The forest
plot of two studies in recently arrived people from countries with high TB burden demonstrated inconsistent
findings (high heterogeneity; I2 = 92%).
Conclusions: Prospective studies comparing IGRA testing against TST on the progression from LTBI to TB were
sparse, and these results should be interpreted with caution due to uncertainty, risk of bias, and unexplained
heterogeneity. Population-based studies with adequate sample size and follow-up are required to adequately
compare the performance of IGRA with TST in people at high risk of TB.
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Background
The timely and accurate identification and prophylactic
treatment of people with latent tuberculosis infection
(LTBI) are important for controlling Mycobacterium tu-
berculosis (TB) worldwide. Once infected with LTBI,
most people remain asymptomatic and are not conta-
gious. However, 5-10% of those infected may progress to
active TB in their lifetime and become infectious [1].
The risk of progression is higher in younger children [2],
people who are immunocompromised or immunosup-
pressed [3, 4], and in people from countries with a high
incidence of TB (≥40 cases per 100,000) [5].
There is no gold standard for the diagnosis of LTBI.
Available screening tests provide indirect information on
the presence of LTBI. Historically, the diagnosis of LTBI
has relied on the use of the tuberculin skin test (TST) [6].
Recently, interferon gamma release assays (IGRAs) have
been developed. These may overcome some of the limita-
tions of TST (e.g., cross-reactivity in Bacilli Calmette-
Guerin vaccinated people, error in measuring the size of
induration of the skin reaction) and can be used as a re-
placement or adjunct to the TST. Currently, two IGRAs
are commercially available: QuantiFERON-TB Gold In-
tube (QFT-GIT) (Cellestis Ltd., Carnegie, Australia) and
T-SPOT.TB (Oxford Immunotec Ltd, Oxford, UK).
Since the introduction of IGRAs, an increasing num-
ber of studies has compared their performance with TST
for identification of LTBI. In the absence of a gold stand-
ard, these studies have measured a) the association be-
tween test results and surrogate measures (e.g., duration
or proximity of exposure to an index TB case), b) com-
pared specificity of tests in people at low risk of TB (e.g.,
healthy people or people from low TB incidence coun-
tries) or c) compared sensitivity of tests against culture-
confirmed individuals with TB [6]. The results from
these studies may be biased due to exposure misclassifi-
cation. Moreover, the findings from studies using the
diagnosis of TB as a marker for LTBI may also be biased,
given the difference between the two entities.
Other studies have compared the strength of associ-
ation between IGRA and TST test results in relation to
the risk of progression to active TB. The comparison is
based on the assumption that people with LTBI are at
greater risk of progression to active TB compared to
those without it. With this proxy measure, IGRA and
TST tests have been compared for their ability to predict
progression from LTBI to active TB. For example, two
meta-analyses [1, 7] synthesised evidence from primary
studies comparing IGRAs to TST using progression to
active TB as a proxy for LTBI. Although this approach
provides a potentially unbiased estimate of performance,
these meta-analyses had methodological limitations. For
example, the first meta-analysis included and synthesised
studies in which IGRA or TST test positive people were
treated with anti-TB prophylactic agents [7]. However
evidence suggests that the currently available treatments
for LTBI are effective in preventing a reactivation of TB
(60–90%) [5], hence treatments would have had an inde-
pendent impact on the performance of the IGRA and
TST tests. In the second meta-analysis studies of ‘in-
house’ assays were included [1]. Little is known about
the quality and consistency of these tests across clinical
laboratories (UK Standards for Microbiology Investiga-
tions) since they are not subject to the regulations of
commercially developed tests. Finally, none of the two
meta-analyses compared individual IGRAs to TST in
predicting risk of progression to active TB separately in
children, immunocompromised people, and those who
have recently arrived from high TB burden countries.
In this systematic review we aimed to identify, ap-
praise, and synthesise the relevant evidence from
longitudinal cohort studies comparing performance
of both types of IGRA to TST in identifying LTBI
through predicting progression to active TB separ-
ately for children, immunocompromised people, and
those who have recently arrived from high TB bur-
den countries.
Methods
This review was conducted as part of a clinical guideline
commissioned by the National Institute for Health
Research (NIHR) Health Technology Assessment (HTA)
Programme (project number 13/178/01) [8].
Inclusion and exclusion criteria
We included English language reports of head-to-head
comparative cohort studies aimed at identifying LTBI
which followed-up people to incidence of active TB after
testing with IGRAs (QFT-GIT, T-SPOT.TB) and TST
separately in children (<18 years), immunocompromised
people (e.g., people with HIV, transplant recipients,
people receiving or about to start anti-tumour necrosis
factor TNF-α treatment), and people arriving from high
incidence TB areas (annual incidence ≥ 40 per 100,000)
[5]. We excluded studies of people treated with anti-
tuberculosis prophylaxis after testing for LTBI, studies
which used ‘in-house’ assays, and single-arm studies test-
ing people for LTBI with only IGRAs or TST.
Outcomes of interest
The proportion of people progressing to active TB.
Search strategy
We searched MEDLINE (Ovid), The Cochrane Library,
MEDLINE In-Process Citations and Daily Update (Ovid),
EMBASE (Ovid), and Science Citation Index (Web of
Knowledge). Searches were limited to English Language
studies published between January 2009 and June 2015.
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Electronic searches were supplemented by manually
searching reference lists of potentially relevant studies,
contacting experts in the field and screening of manufac-
turers’ and other relevant websites. For unpublished stud-
ies, we searched specific conference proceedings for the
last 5 years. Details of the search strategy can be found in
Additional file 1.
Study selection, data extraction, and risk of bias
assessment
Two independent reviewers (AT and PA) screened the ti-
tles and abstracts of all identified articles, and afterwards
full-texts of potentially relevant articles using pre-piloted
forms. One reviewer (PA) extracted relevant data from
included studies using a pre-piloted data extraction
form. Data extraction was cross-checked by an inde-
pendent reviewer (AT). Data were collected on author,
year, country, and duration of follow-up, population
characteristics (age, sex, sub-group), intervention (types
of IGRAs), comparator (TST, cut-off values), Bacillus
Calmette–Guérin (BCG) status, TB diagnosis, and out-
comes (the proportion of people who progressed to ac-
tive TB). Risk of bias was assessed using the Quality in
Prognosis Studies (QUIPS) tool, developed to appraise
studies reporting the associations between prognostic
factors and health outcomes [9]. The tool addresses the
risk of bias for six domains: patient selection/participa-
tion, study sample attrition, index test measurement,
outcome/construct validity measurement, confounding,
and statistical analysis/outcome reporting. Any disagree-
ments at study selection, data extraction, and risk of bias
assessment phases of the review were resolved by discus-
sions between the two reviewers or through adjudication
of a third independent reviewer.
Data synthesis and analysis
Given the absence of a gold standard for diagnosing
LTBI, the performance of tests was compared using al-
ternative methodology which relies on the validation of
test results against a predetermined validity construct
(i.e. a proxy for a reference standard) – progression to
active TB. For each test (IGRA or TST), the strength of
association between test results and incidence of active
TB was expressed using cumulative incidence ratios
(CIRs; the ratio of active TB incidence in test positives
versus TB incidence in test negatives) with correspond-
ing 95% CIs. A statistically significant estimate of CIR >
1 would indicate that a test (IGRA or TST) has discrim-
inatory power in predicting occurrence of active TB (i.e.
of identifying LTBI). The effect measures comparing
IGRAs to TST were summarised as ratios of CIRs (R-
CIRs) for IGRA vs. TST with 95% CIs. A statistically sig-
nificant estimate of R-CIR > 1 would suggest for example
that an IGRA has a better power of predicting the
occurrence of active TB (i.e., of identifying LTBI) than
TST. Synthesised data were stratified by type of IGRA
(QFT-GIT or T-SPOT.TB) and TST threshold (≥5 mm,
≥ 10 mm, ≥ 15 mm). We have not synthesised data from
studies of QFT-G because this test is no longer commer-
cially available. We used a random-effects model to pool
the summary effect measure (R-CIR) across studies
when deemed appropriate and feasible (e.g., no evidence
of clinical and methodological heterogeneity, the same
cut-off value of TST). We did not pool study results if
there was evidence of important clinical or statistical
heterogeneity or if data were insufficient. The presence
of heterogeneity was judged by visual inspection of for-
est plots of R-CIRs (and degree of overlap across 95%
CIs), formal statistical tests (Chi-square <0.10 and the I2
statistic >50%), or if data permitted a subgroup analysis
with respect to a priori defined factors including: BCG
vaccination status, risk of bias, TST threshold (≥5 mm, ≥
10 mm, ≥ 15 mm) and prevalence of TB in country of
origin. Publication bias exploration, where data permit-
ted, was planned using asymmetry of contour-enhanced
funnel plots from the meta-analyses [10].
Results
Study identification process
Of the 7,611 records identified, 515 were selected for
full-text examination. Of these, 498 records were
excluded. The remaining 17 publications were included
in the review [11–27]. Figure 1 shows the study flow
with reasons for exclusion depicted in the PRISMA flow
diagram [28].
Characteristics of included studies
Of the 17 included studies, five were conducted in
children [11, 13–16], 10 in immunocompromised people
[12, 17–25], and two studies [26, 27] were undertaken in
people recently arrived from countries with a high
incidence of TB. Most were prospective cohort studies
although two [12, 18] (both in immunocompromised
people) were retrospective cohorts. Further details on
baseline characteristics of included studies are provided
in Table 1.
Children
The five studies were undertaken in Germany [11],
Turkey [14], Iran [15], South Africa [13] and South
Korea [16].
Three studies [11, 13, 16] compared QFT-GIT with
TST (5 mm/10 mm). One study [15] compared QFT-G
with TST (10 mm). The prevalence of BCG vaccination
was reported in three studies as ranging from 36 to 94%
[11, 13, 16]. The mean length of follow-up to diagnosis
of active TB ranged from 1 year [15] to 4 years [11, 13].
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Three studies [11, 13, 15] clearly stated the method(s)
used to diagnose TB.
Immunocompromised people
Six of the 10 studies were conducted in South Korea and
Taiwan [17–19, 21–23], one each in Iran [25], Switzerland
[12], and Denmark [20] and the remaining study across
various European countries [24].
In two studies, participants were receiving haemodi-
alysis for end-stage renal disease (ESRD) [19, 25]. Two
other studies included haematopoietic stem cell trans-
plantation candidates [21] and haematopoietic stem cell
transplantation recipients [22]. The remaining six studies
included people with ‘rheumatic disease’ [18], people who
had undergone kidney transplantation [17], people living
with human immunodeficiency virus (PLWHIV) [12],
people being treated for inflammatory arthritis [23],
people being treated for sarcoidosis [20], and participants
with various conditions and diseases (PLWHIV, chronic
renal failure, rheumatoid arthritis, solid-organ transplant
or stem-cell transplantation) [24].
Four studies compared T-SPOT.TB to TST (5 mm/
10 mm) [12, 17, 19, 25], two studies QFT-G to TST
(10 mm) [19] or TST (6 mm/12 mm) [20], four studies
compared QFT-GIT to either TST (5 mm) [18, 21] or TST
10 mm/15 mm [22, 23]. The study undertaken by Sester
and colleagues [24] compared three tests (TST measured at
5 mm, QFT-GIT and T-SPOT.TB). The mean follow-up
duration across studies ranged from 1.2 to 5 years. Seven
studies [17–20, 22–24] reported methods for TB diagnosis.
Fig. 1 PRISMA [28] flow diagram
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People who recently arrived from countries with high TB
incidence
We identified only two studies [26, 27] conducted in
people recently arriving from high TB incidence coun-
tries. These studies were undertaken in Norway [26] and
the Netherlands [27]. The Harstad et al. study [26] in-
cluded adult asylum seekers and the Kik et al. [27] study
adults who were recently exposed to infectious pulmon-
ary TB. Most of the participants in both studies had
arrived from Europe, Africa, and Asia. The studies com-
pared QFT-GIT with TST (≥6 mm and ≥15 mm) [26]
and QFT-GIT/T-SPOT.TB with TST (≥10 mm and ≥
15 mm) [27]. The prevalence of BCG vaccination was
reported in only one of the studies at 81% [27]. Mean
length of follow-up ranged from 2 years [27] to
3 years [26]. Only one study provided sufficient infor-
mation on method(s) used to diagnose TB, which in-
cluded chest radiography, symptoms, smear and/or
culture results [27].
Assessment of risk of bias
The risk of bias by domain and overall is presented in
Table 2. In children, two studies [14, 15] had a high risk
and the remaining three studies a moderate risk of bias
[11, 13, 16]. Most studies had a moderate risk of bias for
misclassification of individuals in relation to construct
validity groups, since no clear definitions and ascertain-
ment methods were provided [11, 13, 15]. In immuno-
compromised people, three studies had an overall high
[12, 19, 25] and another three a moderate risk of bias
[21, 22, 24]. The remaining four studies had a low overall
risk of bias [17, 18, 20, 23]. Five studies [12, 19, 21, 22, 25]
had moderate/high risk of bias for the items of study par-
ticipation, outcome measurement and study confounding.
Of the two studies in a recently arrived people from
high TB burden countries, one study had a high overall
risk of bias [26] and the other, low risk of bias [27]. In
the Harstad study [26], high risk of bias was noted in
most of the bias domains (e.g., the study participation,
prognostic factor measurement, study confounding, and
statistical analysis and reporting domains).
The incidence of active TB following the testing for LTBI
by subgroups of interest
Details on incidence of active TB by LTBI test results are
presented for the subgroups of interest in Table 3.
IGRAs and TST (5 mm) were both significantly effective
across studies in detecting LTBI for children and
Table 2 Risk of bias in studies of active TB incidence comparing IGRA with TST in children, immunocompromised people and
recently arrived people from countries with a high incidence of TB
First author, Year Study
Participation
Study
Attrition
Prognostic Factor
Measurement
Outcome/Construct
Measurement
Study
Confounding
Statistical Analysis
and Reporting
Total ROB
Children
Diel, 2011 [11] Low Low Moderate Moderate Low Low Moderate ROB
Mahomed, 2011 [13] Moderate Moderate Moderate Moderate High Low Moderate ROB
Metin Timur 2014 [14] High High Moderate Moderate High High High ROB
Noorbakhsh 2011 [15] High High High Moderate High High High ROB
Song, 2014 [16] Low Moderate Low High Moderate Low Moderate ROB
Immunocompromised
Elzi, 2011 [12] High Low Low Moderate High Low High ROB
Kim, 2011 [17] Low Low Low Low Moderate Low Low ROB
Kim, 2015 [18] Low Low Low Low High Low Low ROB
Lee, 2009 [19] High Low Low Moderate High Low High ROB
Lee, 2014 [22] High Moderate Moderate Moderate Low Low Moderate ROB
Lee, 2015 [23] Low Low Moderate Low High Low Low ROB
Milman, 2014 [20] Low Low Moderate Low Low Low Low ROB
Moon, 2013 [21] Moderate Low Moderate Moderate Moderate Low Moderate ROB
Sester, 2014 [24] Low Low Moderate Low High Low Moderate ROB
Sherkat, 2014 [25] High High Moderate High High Moderate High ROB
Recent arrivals from countries with a high incidence of TB
Harstad, 2010 [26] High Low High Moderate High High High ROB
Kik, 2010 [27] Low Low Low Low Low Low Low ROB
IGRA interferon gamma release assay, ROB risk of bias, TST tuberculin skin test
Risk of bias item responses (per domain, overall): high, moderate or low
Auguste et al. BMC Infectious Diseases  (2017) 17:200 Page 7 of 13
Table 3 Progression to TB following LTBI testing with IGRAs and TST in children, immunocompromised and recently arrived
immigrants
Study ID (First
author, year)
Total test
results available
Type of IGRA test
and TST (thresholds)
Number of people
with positive results
Number of people
with negative results
People with test positive results
who progressed to TB (n)
People with test negative results
who progressed to TB (n)
Children
Diel, 2011 [11] 104 QFT-GIT 21 83 6 0
TST (≥5 mm) 40 64 6 0
TST (≥10 mm) 40 64 4 2
Mahomed, 2011 [13] 5244 QFT-GIT 2669 2575 39 13
TST (≥5 mm) 2894 2350 40 12
Metin Timur, 2014 [14] 69 QFT-GIT 0 69 0 0
TST (≥15 mm) 69 0 0 0
Noorbakhsh, 2011 [15] 59 QFT-G 18 41 10 0
58 TST (≥10 mm) 8 50 3 7
Song, 2014 [16] 2966 QFT-GIT 317 2649 11 12
2982 TST (≥10 mm) 663 2319 13 10
TST (≥15 mm) 231 2751 13 10
Immunocompromised
Elzi, 2011 [12] 43 T-SPOT.TB 25 18 25 18
44 TST (≥5 mm) 22 22 22 22
Kim, 2011 [17] 265 T-SPOT.TB 89 176 4 0
288 TST (≥5 mm) 26 262 1 3
Kim, 2015a [18] 282 QFT-GIT 7 275 0 1
282 TST (≥5 mm) 12 270 0 1
Lee, 2009 [19] 30 QFT-G 12 18 1 0
T-SPOT.TB 15 17 0 2
TST (≥10 mm) 20 12 1 1
Lee, 2014 [22] 159 QFT-GIT 26 133 3 2
169 TST (≥10 mm) 19 150 0 5
TST (≥15 mm) 12 157 0 5
Lee, 2015b [23] 342 QFT-GIT 103 239 N/A 4
239 TST (≥10 mm) 60 179 2 2
Milman, 2011 [20] 41 QFT-G 0 41 0 0
12 TST (≥10 mm) 0 12 0 0
Moon, 2013 [21] 210 QFT-GIT 40 170 1 1
244 TST (≥5 mm) 39 205 0 2
Sester, 2014 [24] 1238 QFT-GIT 159 1079 3 5
1217 T-SPOT.TB 193 1024 4 6
1282 TST (≥5 mm) 149 1133 4 7
Sherkat, 2014 [25] 44 T-SPOT.TB 6 38 1 0
TST (≥10 mm) 8 36 1 0
Recent arrivals from countries with a high incidence of TB
Harstad, 2010 [26] 815 QFT-GIT 238 577 8 1
TST (≥6 mm) 415 395 8 1
813 TST (≥15 mm) 121 692 3 6
Kik, 2010 [27] 327 QFT-GIT 178 149 5 3
299 T-SPOT.TB 181 118 6 2
339 TST (≥10 mm) 288 51 9 0
322 TST (≥15 mm) 184 138 7 1
N/A not applicable, QFT-G quantiferon gold, QFT-GIT quantiferon gold-in-tube, TB tuberculosis, TST tuberculin skin test, n number
aOne unique study but three sub-groups received testing (TST alone, QFT-GIT alone and TST and QFT-GIT simultaneously)
bPeople with a positive result on QFT-GIT received TB preventative treatment
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immunocompromised people. Among immunocom-
promised people and those recently arrived from high
incidence countries findings were not statistically signifi-
cant for TST (10 mm) in predicting progression to active
TB. Among recent arrivals, T-SPOT.TB test results were
also not statistically significantly associated with progres-
sion to active TB.
Children
QFT-GIT
Fifty-six of the 3007 (1.86%) QFT-GIT-positive children
(4 studies [11, 13, 14, 16]) progressed to active TB com-
pared with 25 of the 5376 (0.46%) QFT-GIT-negative
children (overall crude CIR for QFT-GIT: 1.86/0.46 =
4.01, 95% CI: 2.51, 6.40).
TST (5 mm)
Forty-six of the 2934 (1.56%) TST (≥5 mm)-positive
children (2 studies [11, 13]) progressed to TB compared
with 12 of 2414 (0.49%) TST (<5 mm)-negative children
of whom only 12 (0.49%) progressed to active TB (over-
all crude CIR for TST-5 mm: 1.57/0.50 = 3.14, 95% CI:
1.68, 5.94).
TST (10 mm)
Twenty of the 711 (2.81%) TST (≥10 mm)-positive chil-
dren (3 studies [11, 15, 16]) progressed to TB compared
with 19 of the 2433 (0.78%) TST (<10 mm)-negative
children (crude CIR for TST-10 mm: 2.81/0.78 = 3.60,
95% CI: 1.93, 6.71).
Immunocompromised
IGRAs (QFT-GIT and T-SPOT.TB)
In the immunocompromised population (4 studies
[18, 21, 22, 24]), seven of the 232 (3.02%) QFT-GIT
positive people progressed to active TB compared
with 13 of the 1999 (0.65%) QFT-GIT that tested
negative (crude CIR for QFT-GIT: 3.02/0.65 = 4.65, 95%
CI: 1.87, 11.51). 34 of the 328 (10.37%) T-SPOT.TB posi-
tive people (5 studies [12, 17, 19, 24, 25]) progressed to
TB compared with 26 of the 1273 (2.04%) T-SPOT.TB
that tested negative (crude CIR for T-SPOT.TB: 10.37/
2.04 = 5.08, 95% CI: 3.09, 8.33).
TST (10 mm)
Four of the 107 (3.74%) people with TST (≥10 mm)
(5 studies [19, 20, 22, 23, 25]) progressed to TB com-
pared with eight of 389 (2.06%) with TST (<10 mm)
(crude CIR for TST-10 mm: 3.74/2.06 = 1.82, 95% CI:
0.58, 5.92).
Recent arrivals from countries with a high incidence of TB
IGRAs (QFT-GIT and T-SPOT.TB)
Across two studies [26, 27], 13 of 416 (3.13%) recent ar-
rivals who tested positive with QFT-GIT progressed to
TB compared to four of 726 (0.55%) that tested negative
(crude CIR for QFT-GIT: 3.13/0.55 = 5.69, 95% CI: 1.86,
17.28). Six of 181 (3.31%) people who tested positive
with T-SPOT.TB progressed to TB compared to two of
118 (1.69%) that tested negative (crude CIR for T-
SPOT.TB: 3.31/1.69 = 1.96, 95% CI: 0.40, 9.53).
TST (≥6 mm or ≥10 mm)
In one study [26] TST (≥6 mm) was used as the thresh-
old for a positive test. Results showed that eight of 415
(1.93%) people who tested positive progressed to TB
compared with one of the 395 (0.25%) people who tested
negative (crude CIR for TST-6 mm: 1.93/0.25 = 7.72,
95% CI: 0.96, 60.59). In the other study [27], 9 of the
288 (3.12%) people with a TST (≥10 mm) progressed to
TB as compared to none of the 51(0%) people that
tested negative (crude CIR for TST-10 mm: 3.42, 95%
CI: 0.20, 57.83).
Comparative performance of tests for identifying latent
tuberculosis infection
Children
QFT-GIT vs. TST (≥5 mm) Only two studies were
eligible for pooling R-CIRs and 95% CIs to compare
QFT-GIT and TST (≥5 mm) [11, 13]. The meta-analytic
estimate was not statistically significant between QFT-
GIT and TST (≥5 mm) for identifying LTBI (Fig. 2a;
pooled CIR = 1.11, 95% CI: 0.71, 1.74).
QFT-GIT vs. TST (≥10 mm) The individual results
from two studies tended to favour IGRA (QFT-GIT) to
TST (≥10 mm) [11, 16] (Fig. 2b). We did not pool the R-
CIRs due to significant heterogeneity across the esti-
mates of these studies (p = 0.01, I2 = 83%). Both studies
were at moderate risk of bias, therefore the risk of bias
is less likely to explain this heterogeneity. One potential
source of heterogeneity may have been the difference in
the burden of TB incidence between the two studies.
Specifically, the study which showed non-significant dif-
ference between IGRA and TST [16] was conducted in a
high incidence area (South Korea) as opposed to the
study by Diel et al. (2011) [11], which was conducted in
low TB incidence area (Germany). There has been
evidence showing reduced sensitivity and specificity of
IGRAs in high compared to low TB burden areas, where
the former is represented by high BCG vaccination rates
given at birth [29–33].
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Immunocompromised people
T-SPOT.TB vs. TST (≥10 mm)
The R-CIRs were pooled across two studies that
included an ESRD population (Fig. 2c; pooled R-CIR =
1.01, 95% CI: 0.65, 1.58) [19, 25]. The meta-analytic
estimate comparing the performance between IGRA
(T-SPOT.TB) and TST (≥10 mm) was not statistically
significant. The corresponding R-CIRs for individual
studies were also non-significant: 0.38 (95% CI: 0.05,
2.87) [19] and 1.07 (95% CI: 0.68, 1.68) [25]. We did
not pool the study estimates across different immuno-
compromised populations due to clinical heterogeneity.
People who arrived recently from countries of high TB
burden
QFT-GIT vs. TST (≥15 mm)
Two studies compared QFT-GIT to TST (≥15 mm) for
this population [26, 27]. As Fig. 2d suggests, in the
Harstad et al. study [26], QFT-GIT was in favour over
TST (R-CIR = 6.78, 95% CI: 1.91, 24.10). In contrast, in
the Kik et al. study [27], TST was in favour over QFT-GIT
(R-CIR = 0.27, 95% CI: 0.07, 0.96). The R-CIR estimates
were not pooled due to significant heterogeneity arising
from the opposing findings (Fig. 2d; p <0.01, I2 = 92%).
The a priori defined factors (BCG vaccination status, TST
threshold, risk of bias, and prevalence of TB in country of
origin) could not readily explain this inconsistency. Note
that the two studies differed in the study populations of
asylum seekers [26] vs. immigrants with known contact
with an index case [27]. Moreover, the Kik study [27] ex-
cluded contacts with TST <5 mm which may have influ-
enced test accuracy parameter estimates.
Discussion
This systematic review compared the performance of
IGRAs with TST for identifying LTBI in terms of predict-
ing progression to active TB in children, immunocom-
promised people and people who had recently arrived
from high TB burden countries. There was limited evi-
dence; mostly from studies with moderate to high risk of
bias making it difficult to draw definitive conclusions.
There was largely consistent evidence in favour of each
test predicting progression to active TB, but there was evi-
dence demonstrating that one test outperformed others.
Even within the well-defined population categories of this
study, there was a great deal of heterogeneity across the
R-CIR effect estimates comparing IGRAs to TST, thereby
rendering results inconclusive.
There was no evidence indicating that QFT-GIT was
better or worse than TST (5 mm) in detecting LTBI in
children. This should not be interpreted as the absence
of difference, since the 95% CIs were wide enough to
cover differences of at least moderate size in each direc-
tion either favouring IGRA or TST. When QFT-GIT
was compared with TST (10 mm), the individual study
estimates tended to favour QFT-GIT over TST, but there
was still strong heterogeneity across the studies. One
study [16] showed a non-significant difference between
QFT-GIT and TST (10 mm) in a high TB burden setting
and the other [11] favoured QFT-GIT over TST
(10 mm) in a low TB burden setting. This observation is
consistent with a growing body of evidence showing a
reduced sensitivity and specificity of IGRAs in high
compared with low TB burden areas, the former repre-
sented mostly by developing countries [29–33]. This
Fig. 2 Pooled cumulative incidence ratios for IGRAs versus TST in children, immunocompromised and recently arrivals. a Pooled cumulative
incidence ratio of QFT-GIT versus TST (5 mm) for a child population. b Forest plot of cumulative incidence ratio of QFT-GIT versus TST (10 mm)
for a child population. c Pooled cumulative incidence ratio of T-SPOT.TB versus TST (10 mm) for an immunocompromised population. d Forest
plot of cumulative incidence ratio of QFT-GIT versus TST (15 mm) for a recent arrival population
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heterogeneity in test performance might be explained by
a number of factors relevant to these high TB burden
settings for example BCG vaccination is frequently given
at birth or there may be a higher frequency of exposure
to MTB, different TB transmission dynamics, malnutri-
tion, comorbidity, co-infection with HIV, exposure to
non-tuberculous mycobacterium (NTMs) or helminthic
infection [32–34].
Similarly, there was no evidence indicating that T-
SPOT.TB was better or worse than TST (10 mm) in de-
tecting LTBI in immunocompromised people. Again,
95% CIs were compatible with a wide range of values of
moderate size in both directions.
The findings in two meta-analysed studies of recently
arrived populations from high TB burden areas were in
opposite direction. Specifically, one study [27] demon-
strated that TST (15 mm) outperformed QFT-GIT, while
the other study [26] showed the opposite. The a priori
defined factors (TST threshold, BCG vaccination, risk of
bias and TB burden) could not readily explain the incon-
sistency between these study findings. Other factors,
such as inclusion criteria for study population could
have contributed to this difference. For example, one
study included asylum seekers [26] as opposed to the
other study which included immigrants who had con-
tacts with an index case [27]. In addition, the Kik study
excluded contacts with TST <5 mm [27].
Despite the extensive research in this area, limited evi-
dence is available on progression to TB in untreated
populations following testing with commercial IGRAs/
TST. This is likely to be a reflection of the standard of
care in high-income countries which is to offer anti-
tuberculous treatment to people who test positive.
Moreover, some evidence has indicated that there exists
variability in TB diagnosis across countries and studies,
which further complicates the comparison of diagnostic
accuracy of TB detection tests [35, 36].
The main strength of this systematic review is that
it synthesises the available evidence on progression to
TB in people who have not received anti-TB treat-
ment for LTBI. Moreover, in this review we have
evaluated and compared the performance of IGRA
and TST tests separately in subgroups of children,
immunocompromised, or recently arrived people from
countries with high TB burden.
We identified two [1, 7] systematic reviews and meta-
analyses assessing IGRAs for predicting the incidence of
TB. The first review [1] included studies which used ‘in-
house’ assays to diagnose LTBI, but little is known about
the quality and consistency of these tests across the clin-
ical laboratories (UK Standards for Microbiology Investi-
gations). In addition, people who had indeterminate
results at baseline and progressed to TB were assumed
to have a negative result. Using this method would
decrease the sensitivity and increase the specificity of
the test. The second review [7] included studies where
people received anti-TB preventative treatment. These
studies may be biased as this therapy will decrease the
number of people progressing to TB, underestimating
the magnitude of the effect estimate for any given test.
Since progression to TB is being used as a reference
standard, this will have an impact on the predictive
values or sensitivity and specificity of the test. In our re-
view we included only studies in which people were not
treated with anti-TB prophylactic treatment and were
followed-up to identify progression of TB.
This review has limitations. First, we excluded studies
on incidence of TB following serial testing with IGRAs/
TST. If some time has passed since a person becomes in-
fected with M. bacterium they may have a negative TST
result on initial testing. However, on subsequent TST an
individual may have a positive reaction because the initial
test stimulates their ability to react to the test. This is
commonly referred to as the ‘booster phenomenon.’ Un-
like TST, the use of IGRAs in serial testing does not lead
to a ‘booster phenomenon.’ Despite this, studies using
IGRAs to assess reproducibility can potentially lead to
conversion/reversion of test results, and this can alter the
clinical decision on whether people should be treated for
LTBI. Second, included studies did not stratify results by
BCG status, so we were unable to present information on
people with or without BCG vaccination who tested on
IGRA/TST and further developed TB. Likewise, due to
sparse data in our meta-analyses (maximum of only two
studies pooled), we were unable to construct funnel plots
to investigate the effects of publication bias.
More large prospective longitudinal studies or trials
comparing head-to-head IGRAs versus TST in un-
treated populations would help to elucidate the rela-
tive merits of IGRA and TST tests in identifying
LTBI among different population subgroups. We are
aware of one study, the UK Prognostic Evaluation of
Diagnostic IGRA Consortium (PREDICT) [37], which
will add to existing knowledge as soon as information
becomes available. However, there may not be many
others given the increasing likelihood of treatment for
those testing positively.
Given our findings that tests work but that there is a
lack of evidence on which works best, policy makers and
those selecting tests should consider practical issues such
as the patient population, the availability of tests, and the
patient acceptability of the tests [38]. More specifically,
the knowledge of sensitivity and specificity of each IGRA
and TST for identifying LTBI would also be advantageous.
Should decision-makers decide to test, sensitivity and spe-
cificity estimates would provide valuable information on
the cost-effectiveness of strategies to identify LTBI which
progresses to TB in these populations.
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Conclusions
Longitudinal studies exploring progression rates from LTBI
to active TB in children, immunocompromised people, and
those recently arrived from areas of high TB burden are
sparse. The pooled risk ratios in our analyses did not allow
identification of superiority or of non-inferiority of the dif-
ferent tests investigated. Our findings are based on a limited
number of studies comparing IGRAs with TST, and the re-
sults should be interpreted with caution due to uncertainty,
risk of bias, and heterogeneity. Prospective population-
based studies or trials with an adequate sample size and
follow-up should be conducted in people who are consid-
ered to be at high risk for TB. These studies should employ
standard diagnostic methodology and criteria for ascertain-
ing incident cases of active TB. However, there may be diffi-
culties in conducting such studies due to the increasing use
of treatment for those who test positive.
Additional file
Additional file 1: An example of the search strategy used to identify
relevant papers. (DOCX 16 kb)
Abbreviations
BCG: Bacillus Calmette–Guérin; CI: Confidence intervals; CIR: Cumulative
incidence ratio; ESRD: End-stage renal disease; HTA: Health technology
assessment; IGRA: Interferon gamma release assay; LTBI: Latent tuberculosis
infection; NIHR: National institute for Health Research; NTM: Non-tuberculous
mycobacterium; PICO: Population, intervention, comparator and outcome;
PLWHIV: People living with human immunodeficiency virus;
PRISMA: Preferred reporting items for systematic reviews and meta-analyses;
QFT-G: QuantiFERON®-TB Gold; QFT-GIT: QuantiFERON®-TB Gold In-Tube test;
QUIPS: Quality in prognosis studies; R-CIR: Ratio of cumulative incidence
ratio; ROB: Risk of bias; TB: Mycobacterium Tuberculosis; TNF: Tumour necrosis
factor; TST: Tuberculin skin test
Acknowledgements
This project was funded by the by National Institute for Health Research
Health Technology Assessment Programme (13/178/01) and is published in
full in the Health Technology Assessment journal series. The views and
opinions expressed are those of the authors and do not necessarily reflect
those of the Department of Health.
Funding
This systematic review was funded by the National Institute of Health
Research Health Technology Assessment Programme (NIHR HTA) (13/178/01).
Availability of data and materials
Data available on request from the authors.
Authors’ contributions
PA and AT designed and JP and AT supervised the systematic review.
The systematic searches were performed by RC with input from PA and
AT. NM provided support on the statistical analyses. PA and AT prepared
the manuscript as lead writers. AC and PS co-ordinated the systematic
review. All authors read and approved the final manuscript.
Competing interests
AC is Professor of Public Health & Health Services Research, Warwick Medical.
School, University of Warwick, UK and is a member of the NIHR HTA and
EME Editorial board. AC is also supported by the NIHR Collaboration for
Leadership in Applied Health Research and Care (CLAHRC) West Midlands at
University Hospitals Birmingham NHS Foundation Trust.
Consent of publication
Not applicable.
Ethics approval and consent to participate
Not applicable.
Author details
1Warwick Evidence, Warwick Medical School, University of Warwick, Coventry
CV4 7AL, UK. 2Evidence in Communicable Disease Epidemiology and Control,
Health Sciences, Warwick Medical School, University of Warwick, Coventry,
UK.
Received: 8 September 2016 Accepted: 1 March 2017
References
1. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon- release
assays and tuberculin skin testing for progression from latent TB infection
to disease state: a meta-analysis. Chest. 2012;142(1):63–75.
2. Kasprowicz VO, Churchyard G, Lawn SD, Squire SB, Lalvani A. Diagnosing
latent tuberculosis in high-risk individuals: rising to the challenge in high-
burden areas. J Infect Dis. 2011;204 Suppl 4:S1168–78.
3. Santin M, Munoz L, Rigau D. Interferon- release assays for the diagnosis of
tuberculosis and tuberculosis infection in HIV-infected adults: a systematic
review and meta-analysis. PLoS ONE. 2012;7(3), e32482.
4. Chkhartishvili N, Kempker RR, Dvali N, Abashidze L, Sharavdze L, Gabunia P,
Blumberg HM, Del Rio C, Tsertsvadze T. Poor agreement between
interferon-gamma release assays and the tuberculin skin test among HIV-
infected individuals in the country of Georgia. BMC Infect Dis. 2013;13:513.
5. Public Health England. World Health Organization (WHO) estimates of
tuberculosis incidence by rate, 2012 (sorted by rate). 2014 [cited; Available
from: http://www.hpa.org.uk/web/HPAweb&HPAwebStandard/HPAweb_C/
1195733837507
6. Trajman A, Steffen RE, Menzies D. Interferon-Gamma Release Assays versus
Tuberculin Skin Testing for the Diagnosis of Latent Tuberculosis Infection:
An Overview of the Evidence. Pulm Med. 2013;2013:601737.
7. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-
Kambafwile J, Fielding K, Wilkinson RJ, Pai M. Predictive value of interferon-
gamma release assays for incident active tuberculosis: a systematic review
and meta-analysis. Lancet Infect Dis. 2012;12(1):45–55.
8. Auguste P, Tsertsvadze A, Pink J, Court R, Seedat F, Gurung T, Freeman K,
Taylor-Phillips S, Walker C, Madan J, Kandala NB, Clarke A, Sutcliffe P.
Accurate diagnosis of latent tuberculosis in children, people who are
immunocompromised or at risk from immunosuppression and recent
arrivals from countries with a high incidence of tuberculosis: systematic
review and economic evaluation. Health Technol Assess. 2016;20:38.
9. Hayden JA, van der Windt DA, Cartwright JL, Cote P, Bombardier C. Assessing
bias in studies of prognostic factors. Ann Intern Med. 2013;158(4):280–6.
10. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced
meta-analysis funnel plots help distinguish publication bias from other
causes of asymmetry. J Clin Epidemiol. 2008;61(10):991–6.
11. Diel R, Loddenkemper R, Niemann S, Meywald-Walter K, Nienhaus A.
Negative and positive predictive value of a whole-blood interferon- release
assay for developing active tuberculosis: an update. Am J Respir Crit Care
Med. 2011;183(1):88–95.
12. Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, Hoffmann M,
Bernasconi E, Bassetti S, Battegay M. Improved sensitivity of an interferon-
gamma release assay (T-SPOT.TB) in combination with tuberculin skin test
for the diagnosis of latent tuberculosis in the presence of HIV co-infection.
BMC Infect Dis. 2011;11:319.
13. Mahomed H, Hawkridge T, Verver S, Abrahams D, Geiter L, Hatherill M,
Ehrlich R, Hanekom WA, Hussey GD. The tuberculin skin test versus
QuantiFERON TB Gold in predicting tuberculosis disease in an adolescent
cohort study in South Africa. PLoS ONE. 2011;6(3):e17984. Erratum appears
in PLoS One. 2011;6(6). doi:10.1371/annotation/b371be66-de38-4ed6-b440-
d27c9d7e552c.
14. Metin Timur O, Tanir G, Oz FN, Bayhan GI, Aydin Teke T, Tuygun N.
Comparison of QuantiFERON-TB gold in-tube test with tuberculin skin test
in children who had no contact with active tuberculosis case. Tuberkuloz ve
Toraks. 2014;62(2):116–21.
Auguste et al. BMC Infectious Diseases  (2017) 17:200 Page 12 of 13
15. Noorbakhsh S, Mousavi J, Barati M, Shamshiri AR, Shekarabi M, Tabatabaei A,
Soleimani G. Evaluation of an interferon-gamma release assay in young
contacts of active tuberculosis cases. East Mediterr Health J. 2011;17(9):714–8.
16. Song SE, Yang J, Lee KS, Kim H, Kim YM, Kim S, Park MS, Oh SY, Lee JB, Lee
E, Park SH, Kim HJ. Comparison of the tuberculin skin test and interferon
gamma release assay for the screening of tuberculosis in adolescents in
close contact with tuberculosis TB patients. PLoS ONE. 2014;9(7), e100267.
17. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, Jung JH, Kim YH, Kim
SC, Choi SH, Jeong JY, Kim YS, Woo JH, Park SK, Park JS, Han DJ. A
prospective longitudinal study evaluating the usefulness of a T-cell-
based assay for latent tuberculosis infection in kidney transplant
recipients. Am J Transplant. 2011;11(9):1927–35. Erratum appears in Am
J Transplant. 2011 Nov;11(11):2541.
18. Kim JH, Won S, Choi CB, Sung YK, Song GG, Bae SC. Evaluation of the
usefulness of interferon-gamma release assays and the tuberculin skin test
for the detection of latent Mycobacterium tuberculosis infections in Korean
rheumatic patients who are candidates for biologic agents. Int J Rheum Dis.
2015;18(3):315–22.
19. Lee SSJ, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, Tsai HC, Wann SR, Lin
HH, Liu YC. High prevalence of latent tuberculosis infection in patients in
end-stage renal disease on hemodialysis: Comparison of quantiFERON-TB
GOLD, ELISPOT, and tuberculin skin test. Infection. 2009;37(2):96–102.
20. Milman N, Soborg B, Svendsen CB, Andersen AB. Quantiferon test for tuberculosis
screening in sarcoidosis patients. Scand J Infect Dis. 2011;43(9):728–35.
21. Moon SM, Lee SO, Choi SH, Kim YS, Woo JH, Yoon DH, Suh C, Kim DY, Lee
JH, Lee JH, Lee KH, Kim SH. Comparison of the QuantiFERON-TB Gold In-
Tube test with the tuberculin skin test for detecting latent tuberculosis
infection prior to hematopoietic stem cell transplantation. Transpl Infect Dis.
2013;15(1):104–9.
22. Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Kim DY, Lee JH, Lee KH, Kim SH.
A prospective longitudinal study evaluating the usefulness of the interferon-
gamma releasing assay for predicting active tuberculosis in allogeneic
hematopoietic stem cell transplant recipients. J Infect. 2014;69(2):165–73.
23. Lee H, Park HY, Jeon K, Jeong BH, Hwang JW, Lee J, Cha HS, Koh EM, Kang
ES, Koh WJ. QuantiFERON-TB gold in-tube assay for screening arthritis
patients for latent tuberculosis infection before starting anti-tumor necrosis
factor treatment. PLoS ONE. 2015;10:3.
24. Sester M, Van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG,
Dominguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti
D, Janssens JP, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A,
Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T,
Yalcin A, Lange C. Tbnet. Risk assessment of tuberculosis in
immunocompromised patients. A TBNET study. Am J Respir Crit Care Med.
2014;190(10):1168–76.
25. Sherkat R, Yaran M, Shoaie P, Mortazavi M, Shahidi S, Hamidi H, Seirafian S,
Taheri S, Farajzadegan Z, Rostami S. Concordance of the tuberculin skin test
and T-SPOT ().TB test results in kidney transplant candidates. J Res Med Sci.
2014;19 Suppl 1:S26–9.
26. Harstad I, Heldal E, Steinshamn SL, Garasen H, Winje BA, Jacobsen GW.
Screening and treatment of latent tuberculosis in a cohort of asylum
seekers in Norway. Scandinavian Journal of Public Health. 2010;38(3):275–82.
27. Kik SV, Franken WP, Mensen M, Cobelens FG, Kamphorst M, Arend SM,
Erkens C, Gebhard A, Borgdorff MW, Verver S. Predictive value for
progression to tuberculosis by IGRA and TST in immigrant contacts. Eur
Respir J. 2010;35(6):1346–53.
28. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for
systematic reviews and meta-analyses: the PRISMA statement. Ann Intern
Med. 2009;151(4):264–9. W264.
29. Dinnes J, Deeks J, Kunst H, Gibson A, Cummins E, Waugh N, Drobniewski F,
Lalvani A. A systematic review of rapid diagnostic tests for the detection of
tuberculosis infection. Health Technol Assess. 2007;11(3):1–196.
30. Machingaidze S, Wiysonge CS, Gonzalez-Angulo Y, Hatherill M, Moyo S,
Hanekom W, Mahomed H. The utility of an interferon gamma release assay
for diagnosis of latent tuberculosis infection and disease in children: a
systematic review and meta-analysis. Pediatr Infect Dis J. 2011;30(8):694–700.
31. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the
diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;
149(3):177–84.
32. Dheda K, Van Zyl SR, Badri M, Pai M. T-cell interferon- release assays for the
rapid immunodiagnosis of tuberculosis: Clinical utility in high-burden vs.
low-burden settings. Curr Opin Pulm Med. 2009;15(3):188–200.
33. Mandalakas AM, Detjen AK, Hesseling AC, Benedetti A, Menzies D.
Interferon-gamma release assays and childhood tuberculosis: systematic
review and meta-analysis. Int J Tuberc Lung Dis. 2011;15(8):1018–32.
34. Adetifa IM, Ota MO, Jeffries DJ, Hammond A, Lugos MD, Donkor S, Patrick
O, Adegbola RA, Hill PC. Commercial interferon gamma release assays
compared to the tuberculin skin test for diagnosis of latent Mycobacterium
tuberculosis infection in childhood contacts in the Gambia. Pediatr Infect
Dis J. 2010;29(5):439–43.
35. Hesseling AC, Schaaf HS, Gie RP, Starke JR, Beyers N. A critical review of
diagnostic approaches used in the diagnosis of childhood tuberculosis. The
International Journal of Tuberculosis and Lung Disease. 2002;6(12):1038–45.
36. TB CARE I. International Standards for Tuberculosis Care. 3rd ed. The Hague:
TB CARE I; 2014.
37. Jackson C, Southern J, Whitworth H, Scott M, Tsou C-Y, Sridhar S, Nikolayevskyy
V, Lipman M, Sitch A, Deeks J, Griffiths C, Drobniewski F, Lalvani A, Abubakar I.
S57 Diabetes and latent tuberculosis infection: nested case-control study
within the PREDICT cohort. Thorax. 2013;68 Suppl 3:A31–2.
38. Sollai S, Galli L, De Martino M, Chiappini E. Systematic review and meta-
analysis on the utility of Interferon-gamma release assays for the diagnosis
of Mycobacterium tuberculosis infection in children: a 2013 update. BMC
Infect Dis. 2014;14(1):S6.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Auguste et al. BMC Infectious Diseases  (2017) 17:200 Page 13 of 13
